<DOC>
	<DOCNO>NCT00032825</DOCNO>
	<brief_summary>This study determine maximum dose docetaxel give safely combination ketoconazole treat advanced prostate cancer . Docetaxel approve treatment several type cancer ; ketoconazole approve antifungal medication also commonly use high dos treat prostate cancer . Patients 18 year age old advanced prostate cancer respond hormone therapy may eligible study . Candidates screen blood test evaluate liver , kidney organ function x-ray , scan , image test determine extent disease . Participants take follow medication : - Docetaxel daily , infuse vein 30 minute , 4-week cycles-3 consecutive week drug follow one week rest - Dexamethasone , 12 hour 1 hour 12 hour docetaxel infusion help prevent fluid retention cause docetaxel - Ketoconazole , 3 time day - Hydrocortisone , twice day replace loss natural steroid cause ketoconazole Patients hospitalize 1 2 day first second dos docetaxel allow frequent blood draw measure blood level drug . Ketoconazole start 2 week first dose docetaxel second dose docetaxel give 2 day . In order determine maximum tolerate dose docetaxel , first patient study give low dose drug , subsequent patient get increasingly high dos unacceptable side effect occur . Because prostate cancer cell may grow expose testosterone , patient may testosterone production suppress either surgically ( removal testicle ) medically injection leuprolide goserelin , luteinizing hormone-release hormone agonists reduce amount testosterone . Imaging study , x-ray , bone scan compute tomography ( CT ) scan , do every 3 month examine tumor respond therapy . After six treatment cycle , patient monthly chest x-rays check fluid around line lung , may occur result docetaxel therapy . Treatment expect continue least 3 6 month , although time could shorten extended depend tumor response therapy side effect drug . Patients experience bad side effect whose tumor grow first 3 treatment cycle continue treatment ; experience unacceptable side effect take study .</brief_summary>
	<brief_title>Ketoconazole Plus Docetaxel Treat Prostate Cancer</brief_title>
	<detailed_description>High dose ketoconazole weekly docetaxel show activity androgen independent prostate cancer ( AIPC ) . We demonstrate synergy prostate cancer vitro model . This open label phase I study high-dose ketoconazole plus weekly docetaxel patient metastatic AIPC . The primary objective study determine side effect profile ketoconazole combine weekly docetaxel therapy determine maximum tolerate dose ( MTD ) recommend phase II dose ( RPIID ) docetaxel combine high dose ketoconazole . Since ketoconazole may alter metabolism docetaxel , study evaluate potential drug interaction adverse event two agent . Ketoconazole dose 600mg per day ( give 200 mg , three time day ) , plus 30mg hydrocortisone ( 20mg morning 10mg evening ) , plus docetaxel 10-43 mg/m ( 2 ) dose escalation , repeat 28-day cycle , comprise weekly treatment three consecutive week follow one week . Each patient evaluate every four week duration study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients must histopathological documentation prostate cancer confirm Pathology Department Clinical Center National Institutes Health National Naval Medical Center prior start study . Patients whose pathology specimens longer available may enrol trial , patient clinical course consistent prostate cancer pathologic documentation diagnosis . Patients must metastatic progressive androgenindependent prostate cancer ( progressive prostate cancer continue receive hormonal ablation , LHRH agonist ) document prior entry . Progression must document least one follow parameter : 1 . Two consecutively rise PSA level , separate least one week , least one measurement 50 % nadir reach last therapeutic maneuver ( long measurement 5 ng/ml great ) ; and/or , 2 . At least one new metastatic deposit Tc99 bone scintigraphy ; and/or , Progression soft tissue metastasis measure appropriate modality ( i.e. , image , palpation ) : 1 . Development new area malignant disease ( measurable nonmeasurable ) ; 2 . Measurable disease progression RECIST criterion ; 3 . At least 4 week flutamide 6 week bicultamide nilutamide . Patients undergone surgical castration must continue treatment LHRH agonist . If reason LHRH agonist discontinue prior entry study , reinstituted disease progression must document . Patients must life expectancy 3 month . Patients must performance status 0 2 accord ECOG criterion . Patients must recover acute toxicity relate prior therapy , include surgery . Hematological eligibility parameter ( within 2 week start therapy ) : 1 . Granulocyte count great equal 1,500/mm ( 3 ) 2 . Platelet count great equal 100,000/mm ( 3 ) Biochemical eligibility parameter ( within 2 week start therapy ) : 1 . If creatinine great 1.5 mg/dl , 24 hour urine collection must obtain , measure creatinine clearance must least 40 mL/min . 2 . Hepatic function : Hepatic : Bilirubin le 1.0 mg/dl , AST ALT less 2.5 time upper limit normal . If alkaline phosphatase great 2.5 time upper limit normal , must fractionate hepatic alkaline phosphatase less 2.5 time upper limit normal . Hormonal profile patient prostate cancer 1 . All patient undergone surgical castration must serum testosterone 50 ng/ml continue GnRh agonist . Patients must active malignancy ( within past two year exception nonmelanoma skin cancer carcinoma situ bladder ) . Patients history unstable newly diagnose angina pectoris , recent myocardial infarction ( within 6 month enrollment ) , New York Heart Assoc . class IIIV congestive heart failure eligible . Patients must able understand sign inform consent form . Patients must willing travel home NIH followup visit . Patients must great equal 18 year age . Must able ingest oral medication eligible . EXCLUSION CRITERIA : Patients brain metastasis eligible . Patients receive strontium samarium eligible . HIVpositive patient receive combination antiretroviral therapy exclude possible pharmacokinetic interaction ketoconazole , docetaxel agent administer study . In fact , ketoconazole find increase toxic effect several protease inhibitor affect CYP3A4 activity . Patients theophylline exclude . Patients receive cisapride exclude . Patients receive HMGCoA inhibitor ( lovastatin , atorvastatin , simvastatin , pravastatin cerivastatin ) Patients currently take know inhibitor and/or inducer CYP3A4 ; patient take known substrate CYP3A4 evaluate primary investigator . Patients receive terfenadine , midazolam , triazolam , alprazolam , astemizole , loratadine , rifampin , isoniazid , dofetilide , pimozide , sirolimus erythromycin exclude . Because gastric acidity necessary dissolution absorption ketoconazole , concomitant administration drug decrease gastric acid output increase gastric pH ( e.g. , antacid , cimetidine , ranitidine , antimuscarinics , omeprazole , lansoprazole ) may decrease absorption thus prohibit . Patients require warfarin exclude .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 4, 2012</verification_date>
	<keyword>Combination</keyword>
	<keyword>Microtubule</keyword>
	<keyword>Hormonal</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Prostate</keyword>
</DOC>